KFAS
CPRX

Keating Financial Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Keating Financial Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1K Sell
125
-398
-76% -$9.48K ﹤0.01% 1655
2025
Q4 		$12.2K Buy
+523
New +$11.7K ﹤0.01% 1028

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Keating Financial Advisory Services's CPRX Position: Q1 2026 in Review

Keating Financial Advisory Services reduced its Catalyst Pharmaceutical (CPRX) stake by 76% in Q1 2026, selling an estimated $9.48K and leaving 125 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Keating Financial Advisory Services first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.2K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Keating Financial Advisory Services held 125 shares of Catalyst Pharmaceutical worth $3.1K as of Q1 2026.
  • Keating Financial Advisory Services sold 398 Catalyst Pharmaceutical shares in Q1 2026, an estimated $9.48K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #1655 holding.
  • Keating Financial Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Catalyst Pharmaceutical position peaked at $12.2K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.